Biofabri is a biopharmaceutical company of the Zendal group, based in Porriño, Spain, with the aim of researching, developing and manufacturing vaccines for humans. The vaccine would be manufactured and developed by Biofabri in collaboration with the University of Zaragoza, IAVI and the Tuberculosis Vaccine Initiative (TBVI).

Bharat Biotech announced on Wednesday a partnership with Spain’s Biofabri to develop, manufacture and market a new tuberculosis vaccine in 70 countries. Phase 3 clinical trials are expected to start in the coming months.

Biofabri is a biopharmaceutical company of the Zendal group, based in Porriño, Spain, with the aim of researching, developing and manufacturing vaccines for humans. The vaccine would be manufactured and developed by Biofabri in collaboration with the University of Zaragoza, IAVI and the Tuberculosis Vaccine Initiative (TBVI).

The MTBVAC was designed and discovered by the team of Carlos Martín from the University of Zaragoza. MTBVAC is one of the most promising in the current global pipeline of TB vaccines. The only currently available TB vaccine, the Bacillus Calmette-Guérin vaccine (BCG), was developed 100 years ago and has limited efficacy in preventing pulmonary tuberculosis in adults, who, along with adolescents, are the largest spreaders of the disease.

This agreement between Bharat Biotech and Biofabri would guarantee the worldwide production and supply of the future vaccine in more than 70 countries.

dr. Krishna Ella, chairman and general manager of Bharat Biotech, said: “TB infected more than 20% of the world’s population and was the second leading cause of death from infectious diseases after Covid-19.”

Bharat Biotech chose this vaccine candidate because of its advanced stage of clinical development and the extremely promising results of Phase 1 and Phase 2 clinical trials, Ella said. The partnership with BioFabri could make MTBVAC a global TB vaccine, Ella said.


This post Bharat Biotech, Biofabri Tuberculosis Vaccine Agreement was original published at “https://www.financialexpress.com/lifestyle/health/bharat-biotech-biofabri-tie-up-for-tuberculosis-vaccine/2463400/”

LEAVE A REPLY

Please enter your comment!
Please enter your name here